
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.
This reversal follows Sarepta's initial refusal to halt distribution despite a Food and Drug Administration (FDA) request amid safety concerns linked to patient deaths.